Drug name - Zurampic
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8003681 | IRONWOOD PHARMS INC | 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and methyl ester |
Aug, 2025
(2 years from now) | |
| US8546436 | IRONWOOD PHARMS INC | Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof |
Feb, 2032
(9 years from now) | |
| CN101817793A | IRONWOOD PHARMS INC | S-Triazolyl A-Mercaptoacet Anilides As Hiv Reverse Transcriptase Inhibitor |
Aug, 2025
(2 years from now) | |
| CN101817793B | IRONWOOD PHARMS INC | S-Triazolyl Alpha-Mercaptoacetanildes As Inhibitors Of Hiv Reverse Transcriptase |
Aug, 2025
(2 years from now) | |
| CN101083987B | IRONWOOD PHARMS INC | S-Triazolyl Alpha-Mercaptoacetanildes As Inhibitors Of Hiv Reverse Transcriptase |
Aug, 2025
(2 years from now) | |
| CN101083987A | IRONWOOD PHARMS INC | S - Triazolyl A - Hydrosulphonyl Acetanilide As Hiv Revertase Inhibitor |
Aug, 2025
(2 years from now) | |
| CN103298796A | IRONWOOD PHARMS INC | Polymorphic Forms Of 2-(5-Bromo-4-(4-Cyclopropylnaphthalen-1-Yl)-4-1,2,4-Triazol-3- Ylthio) Acetic Acid And Uses Thereof |
Dec, 2031
(9 years from now) | |
| CN103298796B | IRONWOOD PHARMS INC | Polymorphic Forms Of 2 - (5 - -4-(4 - -1 - Yl) -4H-1, 2, 4-Triazole - -3 - Puropose) Acetic Acid And The Use Thereof |
Dec, 2031
(9 years from now) | |
| IN262812B | IRONWOOD PHARMS INC | 2-(5-Bromo-4-(4-Cyclopropylnaphthalen-1-Yl)-4H-1,2,4-Triazol-3-Ylthio)Acetic Acid, Methyl Ester, And 2-Chloro-4-Sulfamoylphenyl Amide |
Aug, 2025
(2 years from now) | |
| IN200701232P4 | IRONWOOD PHARMS INC | 2-(5-Bromo-4-(4-Cyclopropylnaphthalen-1-Yl)-4H-1,2,4-Triazol-3-Ylthio)Acetic Acid And Methyl Ester |
Aug, 2025
(2 years from now) | |
| EP2402011B1 | IRONWOOD PHARMS INC | S-Triazolyl Alpha-Mercaptoacetanilides As Inhibitors Of Hiv Reverse Transcriptase |
Aug, 2025
(2 years from now) | |
| EP1789039B1 | IRONWOOD PHARMS INC | S-Triazolyl Alpha -Mercaptoacetanildes As Inhibitors Of Hiv Reverse Transcriptase |
Aug, 2025
(2 years from now) | |
| EP2402011A1 | IRONWOOD PHARMS INC | S-Triazolyl Alpha-Mercaptoacetanilides As Inhibitors Of Hiv Reverse Transcriptase |
Aug, 2025
(2 years from now) | |
| EP1789039A4 | IRONWOOD PHARMS INC | S-Triazolyl Alpha -Mercaptoacetanildes As Inhibitors Of Hiv Reverse Transcriptase |
Aug, 2025
(2 years from now) | |
| EP1789039A2 | IRONWOOD PHARMS INC | S-Triazolyl Alpha -Mercaptoacetanildes As Inhibitors Of Hiv Reverse Transcriptase |
Aug, 2025
(2 years from now) | |
| EP2135608B8 | IRONWOOD PHARMS INC | S-Triazolyl Alpha -Mercaptoacetanilides As Inhibitors Of Hiv Reverse Transcriptase |
Aug, 2025
(2 years from now) | |
| EP2135608B1 | IRONWOOD PHARMS INC | S-Triazolyl Alpha -Mercaptoacetanilides As Inhibitors Of Hiv Reverse Transcriptase |
Aug, 2025
(2 years from now) | |
| EP2135608A1 | IRONWOOD PHARMS INC | S-Triazolyl Alpha -Mercaptoacetanilides As Inhibitors Of Hiv Reverse Transcriptase |
Aug, 2025
(2 years from now) | |
| EP2658846A2 | IRONWOOD PHARMS INC | Polymorphic Forms Of 2-(5-Bromo-4-(4-Cyclopropylnaphthalen-1-Yl)-4H-1,2,4-Triazol-3-Ylthio) Acetic Acid And Uses Thereof |
Dec, 2031
(9 years from now) | |
| EP2658846A4 | IRONWOOD PHARMS INC | Polymorphic Forms Of 2-(5-Bromo-4-(4-Cyclopropylnaphthalen-1-Yl)-4H-1,2,4-Triazol-3-Ylthio) Acetic Acid And Uses Thereof |
Dec, 2031
(9 years from now) | |
| EP2658846B1 | IRONWOOD PHARMS INC | Polymorphic Forms Of 2-(5-Bromo-4-(4-Cyclopropylnaphthalen-1-Yl)-4H-1,2,4-Triazol-3-Ylthio) Acetic Acid And Uses Thereof |
Dec, 2031
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8283369 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Nov, 2028
(6 years from now) | |
| US8357713 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Nov, 2028
(6 years from now) | |
| US10183012 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Nov, 2028
(6 years from now) | |
| US8546437 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Apr, 2029
(6 years from now) | |
| US8084483 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Aug, 2029
(6 years from now) | |
| US9216179 | IRONWOOD PHARMS INC | Treatment of gout and hyperuricemia |
Aug, 2031
(8 years from now) | |
| US9956205 | IRONWOOD PHARMS INC | Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof |
Dec, 2031
(9 years from now) | |
Drugs and Companies using LESINURAD ingredient
Treatment: Achieving a therapeutic benefit in a subject with gout; treatment of gout; Reduction of serum uric acid levels; treatment of hyperuricemia; treatment of gout; Treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone; Treatment of hyperuricemia; Reduction of serum uric acid levels; Coadministering with allopurinol to reduce serum uric acid (sua) below 4 mg/dl; below 6mg/dl in patients having uric acid deposits; and/or below 6mg/dl with sua intraday change more than 50% and/or adverse event rate less than 15%
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 200MG | TABLET;ORAL | Discontinued |
availability in other generic markets.
Click on the highlighted region to filter.